

# Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection

Oluwasanmi O. Adenaiye, M.B.B.S., M.S.<sup>a</sup>, Jianyu Lai, B.Med., M.P.H.<sup>b</sup>, P. Jacob Bueno de Mesquita, Ph.D.<sup>a</sup>, Filbert Hong, Ph.D.<sup>a</sup>, Somayah Youssefi, Ph.D.<sup>a</sup>, Jennifer German, Ph.D.<sup>a</sup>, S.-H. Sheldon Tai, Ph.D.<sup>a</sup>, Barbara Albert, M.D., M.P.H.<sup>a</sup>, Maria Schanz, B.A., B.S.<sup>a</sup>, Stuart Weston, Ph.D.<sup>c</sup>, Jun Hang, Ph.D.<sup>d</sup>, Christian Fung, M.S.<sup>d</sup>, Hye Kyung Chung, Ph.D.<sup>d</sup>, Kristen K. Coleman, Ph.D.<sup>e</sup>, Nicolae Sapoval, B.S.<sup>f</sup>, Todd Treangen, Ph.D.<sup>f</sup>, Irina Maljkovic Berry, Ph.D.<sup>d</sup>, Kristin Mullins, Ph.D.<sup>g</sup>, Matthew Frieman, Ph.D.<sup>c</sup>, Tianzhou Ma, Ph.D.<sup>b</sup>, Donald K. Milton, M.D., Dr.P.H.<sup>a</sup> for the University of Maryland StopCOVID Research Group<sup>\*</sup>

<sup>a</sup> Public Health Aerobiology and Biomarker Laboratory, Institute for Applied Environmental Health, University of Maryland School of Public Health, College Park, Maryland, USA

<sup>b</sup> Department of Epidemiology and Biostatistics, University of Maryland School of Public Health, College Park, Maryland, USA

<sup>c</sup> Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA

<sup>d</sup> Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

<sup>e</sup> Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore

<sup>f</sup> Department of Computer Science, Rice University, Houston, Texas, USA

<sup>g</sup> Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA

<sup>\*</sup> Dr. Donald K. Milton, University of Maryland School of Public Health, 4200 Valley Drive, College Park, MD 20742 email: [dmilton@umd.edu](mailto:dmilton@umd.edu); phone: 301-405-0389 (Alternate: Dr. Filbert Hong, at the same address, email [fhong@umd.edu](mailto:fhong@umd.edu), phone: 301-405-4081)

Key words: SARS-CoV-2; exhaled breath aerosol; face masks; airborne infection; SARS-CoV-2 variants

Running Title: SARS-CoV-2 in Exhaled Aerosols

## Key Points:

- Cases exhale infectious viral aerosols
- SARS-CoV-2 evolution favors more efficient aerosol generation.
- Loose-fitting masks moderately reduce viral RNA aerosol.
- Ventilation, filtration, UV air sanitation, and tight-fitting masks are needed to protect vulnerable people in public-facing jobs and indoor spaces.

38  
39

## 40 **Abstract**

41

42 **Background:** SARS-CoV-2 epidemiology implicates airborne transmission; aerosol infectiousness and  
43 impacts of masks and variants on aerosol shedding are not well understood.

44 **Methods:** We recruited COVID-19 cases to give blood, saliva, mid-turbinate and fomite (phone) swabs,  
45 and 30-minute breath samples while vocalizing into a Gesundheit-II, with and without masks at up to  
46 two visits two days apart. We quantified and sequenced viral RNA, cultured virus, and assayed sera for  
47 anti-spike and anti-receptor binding domain antibodies.

48 **Results:** We enrolled 49 seronegative cases (mean days post onset  $3.8 \pm 2.1$ ), May 2020 through April  
49 2021. We detected SARS-CoV-2 RNA in 45% of fine ( $\leq 5 \mu\text{m}$ ), 31% of coarse ( $> 5 \mu\text{m}$ ) aerosols, and  
50 65% of fomite samples overall and in all samples from four alpha-variant cases. Masks reduced viral  
51 RNA by 48% (95% confidence interval [CI], 3 to 72%) in fine and by 77% (95% CI, 51 to 89%) in  
52 coarse aerosols; cloth and surgical masks were not significantly different. The alpha variant was  
53 associated with a 43-fold (95% CI, 6.6 to 280-fold) increase in fine aerosol viral RNA, compared with  
54 earlier viruses, that remained a significant 18-fold (95% CI, 3.4 to 92-fold) increase adjusting for viral  
55 RNA in saliva, swabs, and other potential confounders. Two fine aerosol samples, collected while  
56 participants wore masks, were culture-positive.

57 **Conclusion:** SARS-CoV-2 is evolving toward more efficient aerosol generation and loose-fitting masks  
58 provide significant but only modest source control. Therefore, until vaccination rates are very high,  
59 continued layered controls and tight-fitting masks and respirators will be necessary.  
60

## 61 Introduction

62  
63 The World Health Organization[1] and U.S. Centers for Disease Control and Prevention[2] recently  
64 acknowledged the growing scientific consensus that inhalation exposure is an important route of SARS-  
65 CoV-2 transmission[3,4]. The totality of evidence from epidemiologic and outbreak investigations,  
66 combined with data on the size distribution of exhaled aerosols and corresponding quantitative models,  
67 is compelling[4]. However, culture of the virus from exhaled aerosols, and direct measures of the  
68 efficacy of face masks as source control when worn by actual patients have been lacking. Previous  
69 reports of infectious virus[5,6] and viral RNA concentrations in room air[7,8] do not provide a clear  
70 picture of how much virus infected persons shed into the air. These gaps lead to uncertainty in estimates  
71 of exposure, derived from retrospective analysis of outbreaks[9]. New variants also appear more  
72 transmissible, but more quantitative data is needed to discern what that means for implementing  
73 effective non-pharmaceutical interventions – still a mainstay of infection protection.  
74

75 We collected exhaled breath aerosol samples from polymerase chain reaction (PCR)-confirmed COVID-  
76 19 cases infected with SARS-CoV-2, including alpha and earlier variants, circulating in a university  
77 campus community using a Gesundheit-II (G-II) exhaled breath sampler[10,11]. We measured  
78 concentrations of SARS-CoV-2 RNA and recovered infectious virus from respiratory swabs, saliva, and  
79 aerosols, analyzed the effectiveness of face masks as source control, and examined the impact of the  
80 alpha variant on aerosol shedding.

## 81 Materials and Methods

82  
83 This study was approved by the University of Maryland Institutional Review Board and the Human  
84 Research Protection Office of the Department of the Navy. Electronically signed informed consent was  
85 obtained and questionnaire data were collected and stored with REDCap[12].  
86

87 We recruited participants with active infection (defined as positive qRT-PCR for SARS-CoV-2 in  
88 respiratory swab or saliva samples) May 2020 through April 2021 from the University of Maryland  
89 College Park campus and community through a) daily symptom reporting and weekly pooled saliva  
90 testing cohort of 238 volunteers, b) direct recruiting of recently diagnosed cases from local clinics and  
91 campus, and c) frequent testing of close contacts of cases for two weeks following last contact. Cases  
92 and contacts completed online consents and a questionnaire (see Supplemental Methods) before in-  
93 person confirmation of consent and specimen collection at the University of Maryland School of Public  
94 Health. For contacts, we collected a blood specimen at the first visit and measured oral temperature,  
95 blood oxygen saturation (SpO<sub>2</sub>), and collected a mid-turbinate swab (MTS) from each nostril and a  
96 saliva sample, at approximately two-day intervals.  
97

98 Cohort members with a positive saliva sample, recently-diagnosed cases, and contacts with a positive  
99 test during follow-up were invited for viral shedding assessment visits on two days separated by one  
100 day. Venous blood was collected at the first visit; MTS, saliva, phone/tablet swab, and 30-minute G-II  
101 exhaled breath samples were collected at each visit[10,11]. To test the effectiveness of masks as source  
102 control, we asked participants to provide paired breath samples at each visit, first while wearing a mask  
103 and then without[13]. We provided a surgical mask at one visit and, to test masks in general use by the  
104 public, we tested the mask brought by the participant at the other; order of mask type was randomized to  
105 avoid bias. Cases studied before September 2020 were asked to repeat the alphabet three times within

106 the 30-minute sampling period, as previously described [13]. Subsequent cases were asked to shout “Go  
107 Terps” 30 times and sing “Happy Birthday” loudly three times at 5, 15, and 25 minutes into each 30-  
108 minute sampling period. Participants with more severe symptoms sometimes opted to give only one 30-  
109 minute breath sample; for these participants, sampling without a face mask was given priority.

#### 110 *Symptom evaluation*

111 Symptoms were self-reported and measured on a scale of 0-3 and composite scores were sums of  
112 individual symptom scores for systemic, gastrointestinal, lower respiratory, and upper respiratory  
113 symptoms as previously described[10], see Supplementary Information [SI] for additional details.

#### 114 *Sample preparation*

115 MTS and phone/tablet swabs were eluted in 1 mL of Universal Transport Media (BD). MTS from both  
116 nostrils were combined. G-II coarse and fine aerosol samples were concentrated, resulting in a 1-mL  
117 final sample volume as previously described.[10] One aliquot each of MTS and saliva samples were  
118 kept at 4 °C for immediate qRT-PCR. All other samples were stored at -80 °C until further analysis.

#### 119 *Laboratory analyses*

120 Specific laboratory analysis details can be found in the SI. Cohort saliva was processed using the  
121 SalivaDirect method[14]. For all other samples, nucleic acids were extracted with MagMax Pathogen  
122 RNA/DNA Kit (Applied Biosystems) on KingFisher Duo Prime (Thermo Scientific), following  
123 manufacturer protocols specific to sample type. Viral RNA was detected and quantified using the  
124 TaqPath COVID-19 Real Time PCR Assay Multiplex and coinfection of samples was determined using  
125 the TaqMan Array Card (both Thermo Scientific). RNA copy numbers are reported per mL for saliva  
126 and per sample for all other sample types. The limit of detection (LOD) was 75 copies/sample and the  
127 limit of quantification (LOQ) was 250 copies/sample (SI).

128 Viral infectivity was measured by first propagating virus on Vero E6 cells stably expressing  
129 TMPRSS2[15] then transferring the media to A549 cells stably expressing human ACE2 (A549-ACE2,  
130 from BEI NR-53522 and a gift from Dr. Adolfo Garcia Sastre). Infected A549-ACE2 cells were  
131 quantified using immunofluorescence staining with anti-SARS-CoV-2 nucleocapsid antibody (Sino  
132 Biological 40143-R004) and Hoechst 33342 (Invitrogen H3570), and imaging with a Celigo Imaging  
133 Cytometer (Nexcelom) (Figures S1, S2). Plasma was analyzed for IgG, IgM, and IgA antibodies to  
134 SARS-CoV-2 using a modified protocol described by Stadlbauer et al., 2020[16]. MTS and saliva  
135 samples were sequenced at the Walter Reed Army Institute for Research or the University of Maryland  
136 Institute for Genome Sciences. SARS-CoV-2 lineages and mutations were determined using  
137 PANGOLIN and Nextstrain tools[17,18].

#### 138 *Statistical analysis*

139 We included analysis of all actively infected cases recruited from the campus and surrounding  
140 community over the course of one year. To ensure comparability of with and without mask samples in  
141 the analysis of mask efficacy, we included only paired same-day samples collected with and without a  
142 face mask from the same person and controlled for numbers of coughs during each sampling session.

143 Data curation, cleaning, analysis, and visualization were performed using R Studio and R (version  
144 4.1.0)[19], with R packages lme4, lme4, and ggplot2[20]. We made group comparison between  
145 seronegative (no detectable antibody) and seropositive cases using two-sample t-test for continuous  
146

152 variables and Fisher's exact test for categorical variables. To handle censored observations below the  
153 limit of detection, we applied linear mixed-effect models with censored responses[21,22] and included  
154 nested random effects of subject and sample nested within subjects. The geometric means and standard  
155 deviations of viral RNA copy numbers for all sample types and the effect of the predictors of viral RNA  
156 shedding were estimated from the model. Deidentified data and code for the accepted manuscript will be  
157 made available on github.  
158

## 159 Results

160  
161 Sixty-one people with active SARS-CoV-2 infection (recent onset and positive PCR for MTS or saliva)  
162 were enrolled in breath testing: 3 from a weekly saliva testing cohort, 43 from 55 recently diagnosed  
163 COVID-19 cases, and 15 from among 62 contacts of cases followed to detect early onset of infection  
164 (Figure S3). Eight people (13%) with active infection had either IgM or IgG antibodies to SARS-CoV-2  
165 spike protein at the first breath testing visit and four were unable to give a venous blood sample.  
166

167 The 57 participants with known serologic status at the time of breath sampling (49 seronegative, 8  
168 seropositive) were enrolled from zero to 12 days post onset of symptoms or first positive test (Table 1,  
169 Figure S4). All cases were asymptomatic or mild at the time of study. The seronegative cases included  
170 all participants with singing experience and alpha-variant infection – there were no other significant  
171 differences based on serologic status. No volunteer was taking antiviral medication at the time of breath  
172 sample collection and no co-infections were identified.  
173

### 174 *Seronegative cases*

175 Among seronegative participants, 4 (8%) were infected with the alpha and none with delta or other  
176 variants associated with increased transmissibility[23] (Table S1). Symptoms tended to be more  
177 pronounced at the first shedding visit, two participants were febrile at the second shedding visit (Figures  
178 S5-S6), and three were asymptomatic. Each of the 4 seronegative alpha variant cases had detectable  
179 concentrations of viral RNA in all MTS, saliva, fomite, and aerosol samples (Table 2). Among the  
180 remaining seronegative participants, we detected viral RNA in all MTS, 99% of saliva, 49% of fomite,  
181 19% of coarse-, and 31% of fine-aerosol samples. The geometric mean concentrations of viral RNA  
182 were significantly greater for all sample types collected from alpha variant cases.  
183

### 184 *Exhaled breath viral RNA from seronegative cases without masks*

185 Viral RNA content of 30-minute breath aerosol samples was similar to the amount of RNA recovered  
186 from participants' mobile phones (Table 2). The frequency of detection of viral RNA in aerosols was  
187 greatest 2-5 days post onset of symptoms or first positive test (Figure S7) but was not a significant  
188 predictor of the quantity of viral RNA in the aerosols (Table 3). Viral RNA in MTS and saliva were  
189 moderately correlated (Figure S8:  $\rho=0.46$ ) but only RNA in MTS was a strong predictor of viral load in  
190 aerosols (Table 3, Figures S9, S10). The quantity of viral RNA in the fine-aerosol fraction was 1.9-fold  
191 (95% confidence interval [CI] 1.2 to 2.9-fold) greater than in the coarse-aerosol fraction (not shown).  
192

### 193 *Effect of alpha variant infection on viral RNA shedding from seronegative cases*

194 Alpha variant infection was associated with significantly greater amounts of viral RNA shedding than  
195 infection with earlier strains and variants. In bivariate analyses of samples collected without masks  
196 (Tables 3 and S3), the alpha variant was associated with significantly greater viral RNA shedding than



197 wild-type and other variants not associated with increased transmissibility. Fine-aerosol shedding  
198 remained significantly greater for alpha variant infections (18-fold, 95% CI, 3.4 to 92-fold) after  
199 adjusting for the increased viral RNA in MTS and saliva, the number of coughs during sampling  
200 sessions, and symptoms (Table 3). We also analyzed the impact of alpha variants on shedding using the  
201 larger data set, including samples collected with and without masks. After controlling for the effect of  
202 masks and numbers of coughs during sampling, alpha variant infection was associated with a 100-fold  
203 (95% CI, 16 to 650-fold) increase in coarse- and a 73-fold (95% CI, 15 to 350-fold) increase in fine-  
204 aerosol RNA shedding (Table 3).

#### 205 *Effect of masks on viral RNA shedding from seronegative cases*

206 We observed statistically significant reductions in aerosol shedding regardless of mask type after  
207 adjusting for number of coughs during sampling sessions: 77% (95% CI, 51% to 89%) reduction for  
208 coarse and 48% (95% CI, 3% to 72%) for fine aerosols (Figure 1). Surgical masks did not perform  
209 significantly differently than others (Table S5), and mask performance was not significantly different for  
210 alpha variant infections (Table 3). The types of face masks brought by participants varied and  
211 progressed from single-layer homemade cloth masks to more substantial double-layer cloth masks,  
212 surgical masks, double masks, and a KN95 over the course of the year (Table S4).

#### 213 *Seropositive cases*

214 Eight participants had antibodies to SARS-CoV-2 spike protein at the time of breath sample collection.  
215 Seropositive cases tended to cough more than seronegative cases (Table 1) but none of the exhaled  
216 aerosol samples from seropositive cases had detectable viral RNA (Table S6).

#### 217 *Virus cultures*

218 Among samples subjected to virus culture, we detected infectious virus (Figure S2) in 50 (68%) of 73  
219 MTS and 20 (32%) of 62 saliva samples from seronegative participants (Figure 2, Table S2a). The RNA  
220 concentration associated with a 50% probability of a positive culture was  $7.8 \times 10^5$  for MTS and  $5.2 \times$   
221  $10^6$  for saliva (Figure S11, Table S7). None of the 75 fine-aerosol samples collected while not wearing  
222 face masks were culture-positive. Two (3%) of the 66 fine-aerosol samples collected from participants  
223 while wearing face masks were culture-positive, including one from a person infected with the alpha  
224 variant 2 days post onset and one from a person with a Nextstrain clade 20G virus 3 days post onset.  
225 Fomite and coarse-aerosol samples subjected to culture were negative.

## 226 Discussion

227 Alpha variant infection yielded one to two orders of magnitude more viral RNA in exhaled breath when  
228 compared with earlier strains and variants not associated with increased transmissibility. Our  
229 observation of increased aerosol shedding, even after controlling for the increased amounts of viral RNA  
230 in the nose and mouth, suggests that evolutionary pressure is selecting for SARS-CoV-2 capable of more  
231 efficient aerosol generation.

232 We recovered infectious virus from two exhaled breath fine-aerosol samples, approximately two-thirds  
233 of MTS, and one-third of saliva samples. Logistic regression analysis of the MTS and saliva samples  
234 suggests that there is a small but measurable probability that each RNA copy represents an infectious  
235 viral particle consistent with previous dose-response models of infectious viruses[24]. The probability of  
236 detecting infectious virus in our cell culture system may be as high as  $10^{-4}$  per RNA copy in saliva  
237 samples with  $10^2$  copies. We recovered infectious virus from one of the two fine-aerosol samples  
238

242 with  $>10^4$  RNA copies per sample, where the estimated probability of a positive culture was 8% per  
243 sample, based on the regression model. The other culture-positive aerosol sample was one of 98 aerosol  
244 samples below the 75-copy limit of detection for RNA. This observation is consistent with a previous  
245 report of infectious SARS-CoV-2 in an aerosol sample with very low RNA copy numbers[5], and may  
246 suggest that virus particles in respiratory aerosols contain fewer defective virions than MTS, or that the  
247 fluid is less likely to interfere with viral cell attachment and entry than are nasal secretions and saliva. It  
248 is likely that human airway epithelium is more susceptible to infection than laboratory cell cultures[25].  
249

250 Loose-fitting face masks, including surgical masks and those in daily use by the study participants,  
251 produced significant, albeit modest, reductions in the amount of viral RNA in exhaled breath, supporting  
252 their use as source control. Consistent with previous studies of influenza, SARS-CoV-2 viral RNA was  
253 shed more abundantly in fine than coarse aerosol and masks were more effective at blocking release of  
254 coarse aerosol[10,13,26,27]. The effectiveness of face masks for blocking release of fine aerosol (1.9-  
255 fold) was similar to the effectiveness we previously reported for influenza (2.8-fold). However, the 4.3-  
256 fold (or 77%) reduction in coarse aerosol was significantly less than the 25-fold reduction previously  
257 observed for influenza shedding[13]. This discrepancy likely arose because the more vigorous and  
258 extended vocalizations in the current study would be expected to maximize leakage around loose-fitting  
259 face masks. Face masks worked equally well for containing alpha variant and “wild-type” aerosol  
260 shedding.  
261

262 Viral RNA aerosol collected from 22 COVID-19 patients in Singapore using a G-II measured similar  
263 RNA copy numbers and overall rates of positive breath samples (59% versus 51% here) during singing  
264 and loud talking as observed here[28]. A majority (68%) of the cases studied in Singapore were infected  
265 by variants associated with increased transmissibility, while 18% of infections were not variants of  
266 concern or interest, and each case was sampled on only one day. By comparison, our sample included  
267 more “wild-type” infections and sampling days per person allowing analysis of the impact of variants on  
268 shedding. One delta variant was studied in Singapore and none in this study. The shedding rates detected  
269 using the G-II in both studies, however, were lower than those reported by Ma et al. using a sampler that  
270 requires subjects to blow through a narrow straw[29]. Ma et al. and our data are in agreement that  
271 among persons infected with “wild-type” strains, a minority (26% and 31%, respectively) shed  
272 detectable levels of viral RNA into aerosols. However, our data on alpha variant infections and the data  
273 from Singapore suggest that this is changing and most cases may now be shedding viral aerosols more  
274 frequently. We have yet to enroll cases with the delta variant and study them using the Maryland  
275 protocol to test the expectation, based on our current findings, that delta will be associated with an  
276 additional large increase in aerosol shedding.  
277

278 Our study had several limitations. Although we attempted to identify and test cases early through weekly  
279 testing of a cohort and intensive follow-up of close contacts, most cases were still studied several days  
280 after onset of symptoms or first positive test. This likely resulted in missing the most contagious  
281 period[30–33]. Furthermore, all cases were mild at the time of testing and only two went on to have  
282 moderate severity and require hospitalization. As a result, our data may not represent the upper end of  
283 the spectrum of shedding. The types of face masks worn by participants changed over the course of the  
284 study, as did the quality of surgical masks that we could purchase. Therefore, we cannot report on the  
285 efficacy of specific loose-fitting masks. This work does, however, provide information on the average  
286 amount of source control provided by community masking. Finally, logistical considerations required

287 that we freeze samples between collection and culture, with potential loss of infectiousness[34],  
288 especially for dilute aerosol specimens.

289  
290 Overall, our results demonstrate that people with mild or asymptomatic SARS-CoV-2 infections  
291 released infectious aerosols in their exhaled breath. Face masks provided significant source control  
292 suggesting that community-wide masking even with loose-fitting masks can reduce viral aerosols in  
293 indoor air by half, making a significant contribution to reducing the spread of COVID-19. Our data also  
294 suggest that the virus is evolving toward more effective dissemination through aerosols and demonstrate  
295 that infectious virus can escape from loose-fitting masks. With the dominance of newer, more  
296 contagious variants than those we studied, increased attention to improved ventilation, filtration, air  
297 sanitation, and use of high-quality tight-fitting face masks or respirators (e.g., tight-fitting ASTM  
298 F3502-21 level-2 face-coverings or respirators) for respiratory protection will be increasingly important  
299 for controlling the pandemic. This will be especially true where vaccination rates are low, vaccine is not  
300 available, and for people with poor immune responses or waning immunity. Therefore, our data support  
301 community mask mandates and tight-fitting masks or respirators for workers in healthcare but also in all  
302 workplaces where people are sharing indoor air or have frequent public contact.

### 306 Acknowledgements

307 We thank Dr. Jacques Ravel, Dr. Luke Tallon, and the Institute of Genome Sciences at the University of  
308 Maryland School of Medicine for performing deep sequencing of SARS-CoV-2 samples. We also thank  
309 Dr. Jamal Fadul and his clinic in College Park, Maryland, for assistance in recruiting study participants.

### 310 Disclaimers and Funding

311 Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its  
312 presentation and/or publication. The investigators have adhered to the policies for protection of human  
313 subjects as prescribed in AR 70–25. The View(s) expressed are those of the authors and do not  
314 necessarily reflect the official views of the Department of Health and Human Services, the Departments  
315 of the Army, Navy or Air Force, the Department of Defense, or the U.S. Government. The findings and  
316 conclusions in this report are those of the authors and do not necessarily represent the official position or  
317 policy of these agencies and no official endorsement should be inferred.

318  
319 This work was supported by Prometheus-UMD, sponsored by the Defense Advanced Research Projects  
320 Agency (DARPA) BTO under the auspices of Col. Matthew Hepburn through agreement N66001-18-2-  
321 4015. This work was also supported by the National Institute of Allergy and Infectious Diseases Centers  
322 of Excellence for Influenza Research and Surveillance (CEIRS), Grant Number HHSN272201400008C,  
323 the Centers for Disease Control and Prevention, Contract Number 200-2020-09528. The findings and  
324 conclusions in this report are those of the authors and do not necessarily represent the official position or  
325 policy of these funding agencies and no official endorsement should be inferred.

326  
327 This work was also supported by a grant from the Bill & Melinda Gates Foundation, and a generous gift  
328 from The Flu Lab (<https://theflulab.org>). The funders had no role in study design, data collection,  
329 analysis, decision to publish, or preparation of the manuscript.



331 None of the authors have a potential conflicting interest or funding source.  
332  
333

## References

1. World Health Organization. Coronavirus disease (COVID-19): How is it transmitted? 2021. Available at: <https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-how-is-it-transmitted>. Accessed 31 May 2021.
2. CDC. Scientific Brief: SARS-CoV-2 Transmission. 2021. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html>. Accessed 8 May 2021.
3. Morawska L, Milton DK. It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis* **2020**; 71:2311–2313.
4. Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. *Lancet* **2021**; 397:1603–1605.
5. Lednicky JA, Lauzardo M, Fan ZH, et al. Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. *Int J Infect Dis* **2020**; 100:476–482.
6. Lednicky JA, Lauzardo M, Alam MDM, et al. Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness. *Infectious Diseases (except HIV/AIDS)*, 2021. Available at: <http://medrxiv.org/lookup/doi/10.1101/2021.01.12.21249603>. Accessed 2 February 2021.
7. Chia PY, Coleman KK, Tan YK, et al. Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. *Nat Commun* **2020**; 11:2800.
8. Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. *Nature* **2020**; 582:557–560.
9. Miller SL, Nazaroff WW, Jimenez JL, et al. Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event. *Indoor Air* **2020**;
10. Yan J, Grantham M, Pantelic J, et al. Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community. *Proc Natl Acad Sci USA* **2018**; 115:1081–1086.
11. McDevitt JJ, Koutrakis P, Ferguson ST, et al. Development and Performance Evaluation of an Exhaled-Breath Bioaerosol Collector for Influenza Virus. *Aerosol Sci Technol* **2013**; 47:444–451.
12. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *Journal of Biomedical Informatics* **2019**; 95:103208.
13. Milton DK, Fabian MP, Cowling BJ, Grantham ML, McDevitt JJ. Influenza virus aerosols in human exhaled breath: particle size, culturability, and effect of surgical masks. *PLoS Pathog* **2013**; 9:e1003205.
14. Vogels CBF, Brackney D, Wang J, et al. SalivaDirect: Simple and sensitive molecular diagnostic test for SARS-CoV-2 surveillance. *Infectious Diseases (except HIV/AIDS)*, 2020. Available at: <http://medrxiv.org/lookup/doi/10.1101/2020.08.03.20167791>. Accessed 17 August 2020.

- 368 15. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-  
369 expressing cells. *PNAS* **2020**; 117:7001–7003.
- 370 16. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed  
371 Protocol for a Serological Assay, Antigen Production, and Test Setup. *Current Protocols in*  
372 *Microbiology* **2020**; 57:e100.
- 373 17. O’Toole Á, Hill V, McCrone JT, Scher E, Rambaut A. cov-lineages/pangolin. CoV-lineages, 2021.  
374 Available at: <https://github.com/cov-lineages/pangolin>. Accessed 15 July 2021.
- 375 18. Trevor Bedford, Richard Nehe, James Hadfield, et al. Nextstrain SARS-CoV-2 resources. 2020.  
376 Available at: <https://nextstrain.org/sars-cov-2/>. Accessed 29 July 2021.
- 377 19. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R  
378 Foundation for Statistical Computing, 2021. Available at: <https://www.R-project.org/>.
- 379 20. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2nd ed. Springer International  
380 Publishing, 2016. Available at: <https://www.springer.com/gp/book/9783319242750>. Accessed 11  
381 June 2020.
- 382 21. Vaida F, Fitzgerald AP, DeGruttola V. Efficient Hybrid EM for Linear and Nonlinear Mixed Effects  
383 Models with Censored Response. *Comput Stat Data Anal* **2007**; 51:5718–5730.
- 384 22. Vaida F, Liu L. Fast Implementation for Normal Mixed Effects Models With Censored Response. *J*  
385 *Comput Graph Stat* **2009**; 18:797–817.
- 386 23. CDC. SARS-CoV-2 Variant Classifications and Definitions. 2021. Available at:  
387 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>. Accessed 12 July 2021.
- 388 24. Haas CN. Estimation of risk due to low doses of microorganisms: a comparison of alternative  
389 methodologies. *Am J Epidemiol* **1983**; 118:573–582.
- 390 25. Pohl MO, Busnadiego I, Kufner V, et al. SARS-CoV-2 variants reveal features critical for  
391 replication in primary human cells. *PLoS Biol* **2021**; 19:e3001006.
- 392 26. Lindsley WG, Noti JD, Blachere FM, et al. Viable influenza A virus in airborne particles from  
393 human coughs. *J Occup Environ Hyg* **2015**; 12:107–113.
- 394 27. Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy  
395 of face masks. *Nat Med* **2020**; 26:676–680.
- 396 28. Coleman KK, Tay DJW, Tan KS, et al. Viral Load of SARS-CoV-2 in Respiratory Aerosols Emitted  
397 by COVID-19 Patients while Breathing, Talking, and Singing. *medRxiv* **2021**;  
398 :2021.07.15.21260561.
- 399 29. Ma J, Qi X, Chen H, et al. COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per  
400 hour. *Clin Infect Dis* **2020**; Available at: [https://academic.oup.com/cid/advance-](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1283/5898624)  
401 [article/doi/10.1093/cid/ciaa1283/5898624](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1283/5898624).

- 402 30. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-  
403 19. *Nature Medicine* **2020**; 26:672–675.
- 404 31. Yang Q, Saldi TK, Gonzales PK, et al. Just 2% of SARS-CoV-2-positive individuals carry 90% of  
405 the virus circulating in communities. *Proc Natl Acad Sci U S A* **2021**; 118:e2104547118.
- 406 32. Jones TC, Biele G, Mühlemann B, et al. Estimating infectiousness throughout SARS-CoV-2  
407 infection course. *Science* **2021**; Available at:  
408 <https://science.sciencemag.org/content/early/2021/05/24/science.abi5273>. Accessed 26 May 2021.
- 409 33. Sun K, Wang W, Gao L, et al. Transmission heterogeneities, kinetics, and controllability of SARS-  
410 CoV-2. *Science* **2021**; 371:eabe2424.
- 411 34. Huang C-G, Lee K-M, Hsiao M-J, et al. Culture-Based Virus Isolation To Evaluate Potential  
412 Infectivity of Clinical Specimens Tested for COVID-19. *J Clin Microbiol* **2020**; 58:e01068-20.

413

414 **Tables**

415

416 **Table 1. Characteristics of the study population**

	Antibody negative	Antibody positive	All with serologic tests	<i>P-value</i> <sup>a</sup>
Number of participants	49	8	57	-
Number of exhaled breath sample visits <sup>b</sup>	78	15	93	-
Female, N (%)	18 (37)	2 (25)	20 (35)	0.70
Age, mean years $\pm$ SD	23.7 $\pm$ 9.5	24.9 $\pm$ 8.4	23.8 $\pm$ 9.3	0.73
Age group, N (%)				-
<18	1 (2)	0 (0)	1 (2)	
18-45	45 (92)	8 (100)	53 (93)	
>45	3 (6)	0 (0)	3 (5)	
White, N (%)	40 (82)	5 (62)	45 (79)	0.16
BMI, mean $\pm$ SD	24.6 $\pm$ 4.5	27.3 $\pm$ 4.8	25 $\pm$ 4.6	0.12
Chronic respiratory illness <sup>c</sup> N (%)	12 (24)	1 (12)	13 (23)	0.67
Ever smoker N (%)	2 (4)	1 (12)	3 (5)	0.37
Has taken singing lessons/part of a choir N (%)	4 (8)	0 (0)	4 (7)	-
Alpha Variant N (%)	4 (8)	0 (0)	4(7)	-
Days post onset <sup>d</sup> mean $\pm$ SD (range)	3.8 $\pm$ 2.1 (Day 1 to 10)	5.9 $\pm$ 3.8 (Day 0 to 12)	4.1 $\pm$ 2.5 (Day 0 to 12)	0.18
Coughs per 30 min, mean $\pm$ SD (range)	1 $\pm$ 3 (0-17)	3 $\pm$ 8 (0-24)	1 $\pm$ 4 (0-24)	0.098
Loss of taste/smell N (%)	13 (27)	4 (50)	17 (30)	0.22
Median upper respiratory symptoms (IQR) <sup>e</sup>	2 (1 - 3)	3 (1.5 - 4)	2 (1 - 3)	0.17
Median lower respiratory symptoms (IQR)	0 (0 - 1.2)	0 (0 - 1)	0 (0 - 1)	0.82
Median systemic symptoms (IQR)	1 (0 - 3)	1 (0 - 2.5)	1 (0 - 3)	0.60
Median gastrointestinal symptoms (IQR)	0 (0 - 1)	0 (0)	0 (0-1)	0.36
Temperature, mean Celsius $\pm$ SD	37.2 $\pm$ 0.4	37.2 $\pm$ 0.2	37.2 $\pm$ 0.3	0.80
Oxygen saturation (SpO <sub>2</sub> ), mean $\pm$ SD	97.9 $\pm$ 1	97.5 $\pm$ 1.1	97.8 $\pm$ 1	0.25

417 BMI, Body mass index; IQR, Interquartile range;



- 418 <sup>a</sup> Group comparisons were made between antibody negative and positive cases using two-sample t-test for continuous variables and  
419 Fisher's exact test for categorical variables.
- 420 <sup>b</sup> 57 volunteers provided breath samples and sera at the initial shedding assessment visit; 34 of them provided exhaled breath samples  
421 at the 2<sup>nd</sup> shedding assessment visit approximately 2 days later; four volunteers who did not provide sera at the first visit were  
422 excluded.
- 423 <sup>c</sup> Chronic respiratory illness = volunteers with any Chronic obstructive pulmonary disease, Asthma, Other lung diseases.
- 424 <sup>d</sup> Days since start of symptoms or first positive test if asymptomatic or presymptomatic to first breath sample; 3 subjects reported no  
425 symptoms.
- 426 <sup>e</sup> Symptoms at the time of each sample collection visit. Sixteen symptoms were rated from 0 to 3 with a maximum possible composite  
427 score of 15 for upper respiratory, 9 for lower respiratory, 12 for systemic symptoms and 12 for gastrointestinal symptoms.

Table 2. Viral RNA from cases seronegative for SARS-CoV-2 antibodies at the first assessment

Sample Type	Variant	Case <sup>a</sup>	Cases with $\geq 1$ positive sample <sup>b</sup>		Samples	Positive Samples <sup>c</sup>		GM (95% CI) <sup>d</sup>	Maximum RNA copies <sup>e</sup>
			$\geq \text{LOD}$	$\geq \text{LOQ}$		$\geq \text{LOD}$	$\geq \text{LOQ}$		
Mid-turbinate swab	Alpha	4	4 (100)	4 (100)	6	6 (100)	6 (100)	$3.8 \times 10^8$ ( $3.3 \times 10^8, 4.4 \times 10^8$ )	$2.9 \times 10^9$
	Other	45	45 (100)	45 (100)	74	74 (100)	73 (99)	$3.8 \times 10^6$ ( $1.4 \times 10^6, 1.0 \times 10^7$ )	$5.1 \times 10^9$
Saliva	Alpha	4	4 (100)	4 (100)	6	6 (100)	6 (100)	$1.9 \times 10^7$ ( $2.7 \times 10^6, 1.3 \times 10^8$ )	$5.2 \times 10^8$
	Other	45	44 (98)	44 (98)	74	73 (99)	70 (95)	$2.1 \times 10^5$ ( $8.1 \times 10^4, 5.4 \times 10^5$ )	$3.9 \times 10^8$
Fomite	Alpha	4	4 (100)	4 (100)	6	6 (100)	4 (67)	560 (530, 590)	$1.7 \times 10^4$
	Other	45	28 (62)	14 (31)	74	36 (49)	17 (23)	46 (17, 120)	$1.2 \times 10^6$
Coarse (>5 $\mu\text{m}$ ) Aerosol	Alpha	4	4 (100)	2 (50)	6	6 (100)	3 (50)	140 (28, 730)	$5.1 \times 10^4$
	Other	45	11 (24)	5 (11)	72	14 (19)	5 (7)	7 (3.2, 15)	$2.6 \times 10^4$
Fine ( $\leq 5 \mu\text{m}$ ) Aerosol	Alpha	4	4 (100)	3 (75)	6	6 (100)	4 (67)	580 (450, 740)	$5.4 \times 10^4$
	Other	45	18 (40)	8 (18)	72	22 (31)	9 (12)	18 (9.1, 34)	$2.8 \times 10^3$

<sup>a</sup> Participants with a mid-turbinate or saliva samples positive for SARS-CoV-2 viral RNA by qRT-PCR and seronegative for SARS-CoV-2 spike protein antibody at enrollment and who provided at least one 30-minute sample of exhaled breath.

<sup>b</sup> Number of participants with at least one sample  $\geq$  limit of detection (LOD) or  $\geq$  limit of quantification (LOQ) (Supplementary).

<sup>c</sup> Samples positive and  $\geq \text{LOD}$  had at least one replicate with confirmed amplification after inspection and quality control (LOD  $\sim 75$  RNA copies with 95% probability of detection) and  $\geq \text{LOQ}$  if the mean of replicate assays was  $\geq 250$  RNA copies.

<sup>d</sup> GM = geometric mean. The GMs were computed, accounting for samples below the LOD, using a linear mixed-effects model for censored responses (R Project LMEC package) using data for all samples of each sample type with nested random effects of samples within study participant.

<sup>e</sup> The largest quantity of RNA copies detected based on the mean of replicates qRT-PCR aliquots.

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/) .

Table 3. Predictors of viral RNA shedding among seronegative participants

	Coarse Aerosol (>5 µm)			Fine Aerosol (≤5 µm)		
	Without Face Mask N=49, n=78 <sup>a</sup>		Paired ± Mask N=46, n = 69	Without Face Mask N=49, n=78		Paired ± Mask N=46, n = 69
	Unadjusted	Adjusted <sup>b</sup>	Estimate <sup>c</sup>	Unadjusted	Adjusted	Estimate
<b>Alpha Variant</b>	67 (6.7, 660)	3.6 (0.35, 36)	100 (16, 650)	43 (6.6, 280)	18 (3.4, 92)	73 (15, 350)
<b>Face mask</b>	-	-	0.23 (0.11, 0.49)	-	-	0.52 (0.28, 0.97)
<b>Age</b>	1.4 (0.44, 4.4)	-	-	1.7 (0.74, 3.7)	1.7 (1, 2.8)	-
<b>Day post onset<sup>e</sup></b>	0.79 (0.53, 1.2)	-	-	0.97 (0.76, 1.2)	-	-
<b>Log mid-turbinate swab</b>	480 (40, 5700)	36 (3.5, 370)	-	13 (4.3, 42)	7.3 (2.5, 21)	-
<b>Log saliva</b>	4.6 (1.4, 15)	1.5 (0.55, 4.3)	-	2.8 (1.2, 6.5)	0.96 (0.47, 2)	-
<b>Number of coughs</b>	1.2 (0.92, 1.5)	1.2 (1, 1.5)	1 (0.93, 1.2)	1.2 (0.96, 1.5)	1.2 (1, 1.3)	1.1 (1, 1.3)
<b>Upper respiratory symptoms</b>	2.4 (0.91, 6.1)	-	-	1.7 (0.83, 3.6)	0.75 (0.44, 1.3)	-
<b>Lower respiratory symptoms</b>	0.99 (0.36, 2.7)	0.4 (0.13, 1.2)	-	0.64 (0.3, 1.4)	-	-
<b>Gastrointestinal symptoms</b>	2.3 (1.1, 5.2)	1.2 (0.55, 2.4)	-	1.7 (0.94, 3.2)	1 (0.61, 1.7)	-
<b>Systemic symptoms</b>	5.7 (2.5, 13)	2.4 (0.97, 6.1)	-	2.1 (1.1, 4)	1.1 (0.59, 2)	-
<b>Alpha Variant x Face mask</b>	-	-	0.62 (0.15, 2.7)	-	-	0.7 (0.2, 2.4)

Effect estimates and their 95% confidence intervals are shown as the ratio of RNA copy number of samples: with alpha variant to without alpha variant, with mask to without mask, or as the fold-increase in RNA copy number for a 10-year increase in age, 1-day increase in day post-symptom onset, and an interquartile range change in symptom scores, mid-turbinate swab and saliva RNA copy number. All

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/) .

analyses were controlled for random effects of subject and sample nested within subjects and for censoring by the limit of detection using a linear mixed-effects model for censored responses (R Project lme4-package).

- <sup>a</sup> N = Number of participants, n = number of samples for without face mask analysis and number of pairs of same day with and without face masks samples for paired analysis of the effect of face masks.
- <sup>b</sup> The adjusted estimates accounted for potential covariates resulting in greater than 10% change in the estimates of the main exposure variable – “Alpha variant”
- <sup>c</sup> The effect of mask on samples adjusted for Alpha variant and number of coughs counted during sample collection
- <sup>d</sup> Face masks included both surgical masks provided by the investigators and masks currently being used by participants on the day of testing; surgical masks and participant provided masks were not significantly different (Table S5).
- <sup>e</sup> Days since start of symptoms or first positive test if asymptomatic or presymptomatic to breath sample; 2 subjects had no symptoms

## FIGURES LEGENDS

**Figure 1.** Viral RNA shedding in paired with and without face mask samples. Viral RNA measured during 69 same-day paired sampling events with and without mask from 46 seronegative cases. Samples with no detected viral RNA were assigned a copy number value of one. Exhaled breath aerosols were obtained in 30-minute sampling durations. “+mask” = sample collected while wearing a face mask. MTS = mid-turbinate swab, Fomite = swab of participant’s mobile phone.

**Figure 2.** Viral RNA content and culture results of samples from all sampling events for seronegative cases. Samples with no detected viral RNA were assigned a copy number value of one. Exhaled breath aerosols were obtained during 30-minute sampling events and included unpaired with and without face mask samples. Five fine aerosol samples with face mask and three fomite samples were not available for culture. A subset of MTS, saliva, and coarse aerosol samples were subjected to culture. MTS = mid-turbinate swab, Fomite = swab of participant’s mobile phone.





